The glycomic therapeutics market is a rapidly growing field in the pharmaceutical industry, with a focus on the development of drugs targeting the carbohydrates present on the surface of cells. These carbohydrates, known as glycans, play a crucial role in many biological processes, including cell-cell communication, immune response, and cancer progression.
The global glycomic therapeutics market is expected to expand at a CAGR of 16.1% during the period 2022-2032. The market is expected to hold a valuation of US$ 551,756 million by 2032, and as of 2022, the market is valued at US$ 124,439 million.
Request For Free Sample Report of “Glycomic Therapeutics Market”@ https://www.persistencemarketresearch.com/samples/33227
One of the major drivers of the glycomic therapeutics market is the increasing understanding of the importance of glycans in disease development and progression. For example, cancer cells often have distinct glycans on their surface that can be targeted with therapeutics. Additionally, many immune-mediated diseases, such as rheumatoid arthritis and lupus, involve abnormal glycans on immune cells.
Another driver of the market is the development of new technologies and techniques for analyzing and manipulating glycans. This has allowed for the identification of new therapeutic targets and the creation of more precise and effective drugs.
Companies
- Intellihep Ltd
- Protalix Biotherapeutics
- BioMarin Pharmaceutical Inc.
- Sanofi
- Halozyme Therapeutics Inc
- Bayer AG
- Alzheon Inc.
- GlycoMar
- GlaxoSmithKline Plc
- Hoffmann-La Roche Ltd
Buy Full Report Now @ https://www.persistencemarketresearch.com/checkout/33227
The glycomic therapeutics market is divided into several sub-markets, including cancer therapeutics, immune-mediated disease therapeutics, and others. Within the cancer therapeutics sub-market, there is a significant focus on developing drugs targeting cancer-associated glycans. In the immune-mediated disease therapeutics sub-market, there is a focus on developing drugs that target abnormal glycans present on immune cells in these diseases.
Several companies are actively developing and commercializing glycomic therapeutics. Some examples include Galectin Therapeutics, which is developing drugs targeting galectin proteins involved in cancer progression, and GlycoMimetics, which is developing drugs targeting abnormal glycans present in sickle cell disease and other conditions.
Overall, the glycomic therapeutics market is expected to continue to grow in the coming years as more drugs targeting glycans are developed and brought to market. As the understanding of the role of glycans in disease continues to deepen, there will likely be even more opportunities for the development of new therapeutics in this field.
Recent Developments
The market is witnessing a lot of strategic partnerships, between the key players and the players operating in other segments of healthcare sector. Apart from that, the market has also been experiencing a number of mergers. The main reasons are expanding the footprints of the market, and also to access certain technologies which were not available with them.
Some of the recent developments are:
In August 2022, the New England Biolabs introduced Faustovirus Capping Enzyme, a Novel Enzymatic mRNA capping solution for mRNA manufacturing.
In October 2022, GSK marketing authorization application for respiratory syncytial virus older adult vaccine candidate accepted by Europe Medicines Agency.
Request Customization @ https://www.persistencemarketresearch.com/request-customization/33227
Glycomic Therapeutics Market Segmentation
By Class:
- Isolated
- Synthetic
By Structures:
- Glycoproteins
- Targeting Sialic Acid
- Proteoglycans
- Targeting Glycosaminoglycans
- Targeting Glycosylphosphatidylinositol (GPI) – Anchored Proteins and Heparin Based Glycans
- Targeting Glycosphingolipids
- Others
By Indications:
- Thrombosis and Chemoprophylaxis
- Anaemia
- Anti-adhesive and Anti-inflammatory
- Cataracts
- Gaucher’s disease
- MPS-1 and IV
- Cancer
- Alzheimer’s disease
- Influenza type A and B
- Others
By Mode of Action:
- Inhibits Neuraminidase
- Inhibits Heparanase and Selectins and Blocks Interactions between Growth Factors and Heparan Sulfate
- Erythropoietin and Enzyme Replacement Therapy
- Tissue Plasminogen Activator
- Inhibits Glucosylceramide Synthase
- Interleukin 1, 2 & 3
- Beta and Gamma Interferons
- Others
For More Premium Insights, Check out the Link:
Botulinum Immunodiagnostics market
Lipopolysaccharides Immunoassay market
Rapid Influenza Diagnostic Tests market
About Us
Persistence Market Research is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. Persistence Market Research boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
Contact Us:
Persistence Market Research
Japan
Persistence Market Research
1-2-1 Kinshi Arca Central Building 14/F Tokyo, 130-0013 Japan
Call 0800-222-1088
United States
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
